Home > Boards > US Listed > Medical - Healthcare > Mylan Inc. (MYL)

Mylan should have a little green stability. HERTFORDSHIRE, England

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
tw0122 Member Profile
 
Followed By 54
Posts 6,707
Boards Moderated 0
Alias Born 08/14/11
160x600 placeholder
Mylan and Development Partner, Synthon, Win Significant European Patent Office Ruling Related to Copaxone® 40mg/mL PR Newswire (US) - 9/15/2020 7:15:00 AM
Mylan and Pfizer Receive European Commission Approval for Proposed Combination of Mylan and Upjohn PR Newswire (US) - 9/15/2020 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/11/2020 5:01:55 PM
Mylan to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference PR Newswire (US) - 9/9/2020 1:07:00 PM
Mylan to Present at the BofA Securities Virtual Global Healthcare Conference PR Newswire (US) - 9/9/2020 1:05:00 PM
Mylan to Acquire Aspen's Thrombosis Business in Europe PR Newswire (US) - 9/8/2020 2:00:00 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 8/31/2020 6:06:03 AM
Mylan and Biocon Biologics Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patien... PR Newswire (US) - 8/31/2020 6:00:00 AM
Mylan Initiates Voluntary Nationwide Recall of Four Lots of Amiodarone HCl Injection, USP and Tranexamic Acid Injection, USP ... PR Newswire (US) - 8/28/2020 6:30:00 PM
Mylan Launches First U.S. Generic of Biogen MS Drug Tecfidera Dow Jones News - 8/19/2020 8:09:00 AM
Mylan Brings Critical Access to the Multiple Sclerosis Community by Launching a More Affordable Treatment Option Through a Fi... PR Newswire (US) - 8/19/2020 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/12/2020 6:02:47 PM
Mylan and Sesame Workshop Partner to Provide Socio-Emotional Support Resources to Families Impacted by COVID-19 PR Newswire (US) - 8/12/2020 9:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2020 5:28:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2020 8:45:22 AM
Mylan Reports Strong Second Quarter and First Half 2020 Results and Updates 2020 Guidance PR Newswire (US) - 8/6/2020 6:30:00 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 7/24/2020 5:22:43 PM
Mylan to Release Second Quarter 2020 Financial Results on Aug. 6, 2020 PR Newswire (US) - 7/22/2020 7:30:00 AM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 7/10/2020 5:22:53 PM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 7/9/2020 5:15:45 PM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 7/9/2020 5:11:08 PM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 7/9/2020 5:08:42 PM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 7/9/2020 5:06:28 PM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 7/9/2020 5:06:04 PM
Viatris Reveals Branding to Reflect New Company's Transformative Strategy PR Newswire (US) - 7/9/2020 8:31:00 AM
tw0122   Saturday, 03/21/20 08:32:57 PM
Re: None
Post # of 224 
Mylan should have a little green stability.
HERTFORDSHIRE, England and PITTSBURGH, March 19, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced its continued commitment to do its part in support of public health needs amidst the evolving COVID-19 pandemic. The company continues to focus its efforts on protecting our employees, producing critically needed medications, and turning our scientific and operational expertise towards identifying additional ways we may be able to assist in the massive prevention, diagnosis and treatment efforts needed to counter the spread of COVID-19.

For example, in the immediate term, Mylan has restarted production of hydroxychloroquine sulfate tablets at its West Virginia manufacturing facility in the U.S. to meet the potential for increased demand resulting from potential effectiveness of the product in treating COVID-19. Mylan's hydroxychloroquine sulfate tablets are approved by the U.S. Food and Drug Administration (FDA) for the treatment of malaria, lupus erythematosus and rheumatoid arthritis. Although the product is not currently approved for use in the treatment of COVID-19, it is listed by the World Health Organization as a drug under investigation for efficacy against the coronavirus[1]. The company is also taking steps to initiate production of this product outside the U.S. in the coming weeks. We look forward to working with governments and health authorities globally to ensure patient access to this medicine as and where needed.

Mylan expects to be in a position to begin supplying product by mid-April, and with the active pharmaceutical ingredient that we currently have available, will be able to ramp up manufacturing to provide 50 million tablets to potentially treat a total of more than 1.5 million patients. The potential use of this medicine for COVID-19 related treatment is pending additional FDA and other regulatory body guidance

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences